Erasca, Inc. (ERAS): Total Liabilities
$70.98M
As of 2025-12-31
$73.19M
As of 2026-06-30
-11.7%
3-year compound annual growth
+32.5%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $70.98M | -10.2% | 2026-03-12, Balance as of period end |
| 2024-12-31 | $79.03M | +0.5% | 2026-03-12, Balance as of period end |
| 2023-12-31 | $78.61M | -23.7% | 2025-03-20, Balance as of period end |
| 2022-12-31 | $103.06M | +129.6% | 2024-03-27, Balance as of period end |
| 2021-12-31 | $44.89M | +157.9% | 2023-03-23, Balance as of period end |
| 2020-12-31 | $17.40M | n/a | 2022-03-24, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Erasca, Inc. (ERAS) | 2025-12-31 | $70.98M | -10.2% |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $52.51M | -55.1% |
| Oncotelic Therapeutics, Inc. (OTLC) | 2025-12-31 | $131.36M | +584.2% |
| Harrow, Inc. (HROW) | 2025-12-31 | $347.39M | +8.7% |
| Nkarta, Inc. (NKTX) | 2025-12-31 | $91.88M | -1.4% |
| MBX Biosciences, Inc. (MBX) | 2025-12-31 | $15.92M | +43.5% |
| Oric Pharmaceuticals, Inc. (ORIC) | 2025-12-31 | $24.53M | -20.9% |
| Zenas BioPharma, Inc. (ZBIO) | 2025-12-31 | $141.50M | +146.0% |
| Xeris Biopharma Holdings, Inc. (XERS) | 2025-12-31 | $369.84M | +4.9% |
Compare ERAS, TNGX, OTLC, HROW side by side · Screen every company in Pharmaceutical Preparations ↗